SCHEMBL2569236

SCHEMBL2569236

COC(=O)C1CC(OS(=O)(=O)c2ccc(C)cc2)CN1C(=O)OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.45
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
POLB P06746 1/20 0.44
KMT2A Q03164 2/20 0.42
LMNA P02545 1/20 0.42
MEN1 O00255 1/20 0.42
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42
MMP7 P09237 1/20 0.42
MMP9 P14780 1/20 0.42
MMP13 P45452 1/20 0.42
TSHR P16473 2/20 0.42
GAA P10253 1/20 0.42
GFER P55789 1/20 0.41
MCL1 Q07820 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HPGD P15428 1/20 0.40
CYP3A4 P08684 2/20 0.40
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7408542 1.00 ELANE (0.45) ELANECA1CA2POLBKMT2A
SCHEMBL29879680 1.00 ELANE (0.45) ELANECA1CA2POLBKMT2A
SCHEMBL2569233 1.00 ELANE (0.45) ELANECA1CA2POLBKMT2A
SCHEMBL2569312 1.00 ELANE (0.45) ELANECA1CA2POLBKMT2A
SCHEMBL5764432 1.00 ELANE (0.45) ELANECA1CA2POLBKMT2A
SCHEMBL7408543 1.00 ELANE (0.45) ELANECA1CA2POLBKMT2A
SCHEMBL16256989 0.94 ELANE (0.49) ELANECA1CA2POLBLMNA
SCHEMBL29510702 0.94 ELANE (0.49) ELANECA1CA2POLBLMNA
SCHEMBL8481733 0.92 GAA (0.46) ELANECA1CA2POLBKMT2A
SCHEMBL7301497 0.92 GAA (0.46) ELANECA1CA2POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069354-B1 Aza-benzofuranyl compounds and methods of use GENENTECH INC (US) 2011-11-02 EP disclosed
EP-2069354-A1 AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2009-06-17 EP disclosed
US-20080085886-A1 Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide GENENTECH, INC. 2008-04-10 US disclosed
WO-2008024725-A1 AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085886-A1 Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide MAP3K2, MAP3K1, MAP2K2 ELANE 832/4885CA1 3340/4885CA2 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.